Ganesan Vaidyanathan Selected Research

N-succinimidyl 4-guanidinomethyl-3-iodobenzoate

1/2022	Evaluation of an 131I-labeled HER2-specific single domain antibody fragment for the radiopharmaceutical therapy of HER2-expressing cancers.
1/2021	Site-specific radioiodination of an anti-HER2 single domain antibody fragment with a residualizing prosthetic agent.
1/2020	Labeling a TCO-functionalized single domain antibody fragment with 18F via inverse electron demand Diels Alder cycloaddition using a fluoronicotinyl moiety-bearing tetrazine derivative.
10/2019	Observations on the Effects of Residualization and Dehalogenation on the Utility of N-Succinimidyl Ester Acylation Agents for Radioiodination of the Internalizing Antibody Trastuzumab.
1/2019	Labeling Single Domain Antibody Fragments with Fluorine-18 Using 2,3,5,6-Tetrafluorophenyl 6-[18F]Fluoronicotinate Resulting in High Tumor-to-Kidney Ratios.
12/2018	An Efficient Method for Labeling Single Domain Antibody Fragments with 18F Using Tetrazine- Trans-Cyclooctene Ligation and a Renal Brush Border Enzyme-Cleavable Linker.
1/2018	Fluorine-18 labeling of an anti-HER2 VHH using a residualizing prosthetic group via a strain-promoted click reaction: Chemistry and preliminary evaluation.
1/2018	Astatine-211 labeled anti-HER2 5F7 single domain antibody fragment conjugates: radiolabeling and preliminary evaluation.
11/2014	N-Succinimidyl guanidinomethyl iodobenzoate protein radiohalogenation agents: influence of isomeric substitution on radiolabeling and target cell residualization.
4/2014	Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ganesan Vaidyanathan Research Topics

Disease

44	Neoplasms (Cancer) 05/2022 - 01/2002
13	Breast Neoplasms (Breast Cancer) 05/2022 - 08/2009
9	Glioma (Gliomas) 02/2014 - 01/2002
5	Brain Neoplasms (Brain Tumor) 09/2020 - 02/2009
4	Carcinoma (Carcinomatosis) 01/2022 - 04/2014
4	Prostatic Neoplasms (Prostate Cancer) 01/2022 - 10/2016
4	Neuroblastoma 11/2007 - 09/2004
3	Neuroendocrine Tumors (Neuroendocrine Tumor) 08/2015 - 04/2004
3	Medulloblastoma 01/2010 - 05/2003
2	Neoplasm Metastasis (Metastasis) 03/2021 - 10/2011
2	Neoplasm Micrometastasis 10/2016 - 09/2008
2	Glioblastoma (Glioblastoma Multiforme) 01/2012 - 10/2010
1	Residual Neoplasm 09/2008
1	Meningitis 12/2004
1	Pancreatic Neoplasms (Pancreatic Cancer) 05/2003

Drug/Important Bio-Agent (IBA)

19	N-succinimidyl 4-guanidinomethyl-3-iodobenzoateIBA 01/2022 - 01/2002
8	Single-Domain AntibodiesIBA 05/2022 - 01/2013
8	Monoclonal AntibodiesIBA 09/2020 - 01/2002
8	ErbB Receptors (EGF Receptor)IBA 01/2019 - 01/2002
7	Trastuzumab (Herceptin)FDA Link 10/2019 - 08/2009
7	Proteins (Proteins, Gene)FDA Link 12/2018 - 04/2006
6	3-Iodobenzylguanidine (Iobenguane)IBA 08/2015 - 04/2004
5	RadiopharmaceuticalsIBA 01/2022 - 11/2007
5	AntigensIBA 01/2022 - 10/2007
5	Radioisotopes (Radionuclides)IBA 03/2021 - 09/2008
5	Peptides (Polypeptides)IBA 01/2015 - 05/2003
5	1,3,4,6-tetrachloro-3 alpha,6 alpha-diphenylglycolurilIBA 08/2009 - 03/2003
4	AntibodiesIBA 01/2022 - 01/2013
4	epidermal growth factor receptor VIIIIBA 10/2010 - 01/2002
3	EnzymesIBA 07/2018 - 11/2009
3	Norepinephrine Plasma Membrane Transport Proteins (Norepinephrine Transporter)IBA 08/2015 - 05/2007
3	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 01/2010 - 05/2003
3	Octreotide (Sandostatin)FDA LinkGeneric 11/2007 - 05/2003
2	GoldIBA 07/2019 - 01/2015
2	Amino Acid Transport Systems (Amino Acid Transporter)IBA 01/2017 - 10/2011
2	DNA alkyltransferaseIBA 01/2011 - 04/2006
2	Alkylating AgentsIBA 01/2011 - 04/2006
2	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA 10/2010 - 01/2010
2	Glucose (Dextrose)FDA LinkGeneric 01/2010 - 05/2003
2	Somatostatin Receptors (Somatostatin Receptor)IBA 11/2007 - 12/2004
1	LigandsIBA 03/2021
1	human ERBB2 proteinIBA 10/2019
1	Fluorine-18IBA 01/2019
1	1,4,7- triazacyclononane- N,N',N''- triacetic acid (NOTA)IBA 12/2018
1	pertuzumabIBA 12/2017
1	EpitopesIBA 12/2017
1	Essential Amino AcidsIBA 01/2017
1	Leucine (L-Leucine)FDA Link 01/2017
1	LuciferasesIBA 10/2016
1	Urea (Carbamide)FDA LinkGeneric 10/2016
1	Growth Factor ReceptorsIBA 01/2016
1	Heat-Shock Proteins (Heat-Shock Protein)IBA 09/2013
1	Chloroquine (Aralen)FDA LinkGeneric 01/2012
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2012
1	Aldehyde DehydrogenaseIBA 01/2012
1	RadiumIBA 10/2011
1	4-iodophenylalanineIBA 10/2011
1	Amino Acids FDA Link 10/2011
1	Phenylalanine (L-Phenylalanine)FDA Link 10/2011
1	MucinsIBA 10/2010
1	SialoglycoproteinsIBA 10/2010
1	Tyr(3)- octreotateIBA 01/2010
1	Astatine-211IBA 10/2007
1	alpha-naphthoflavoneIBA 04/2006
1	Cytochrome P-450 Enzyme System (Cytochrome P450)IBA 04/2006
1	Cytochrome P-450 CYP1A2 (CYP1A2)IBA 04/2006
1	IsoenzymesIBA 04/2006
1	NucleosidesIBA 04/2006
1	Single-Chain AntibodiesIBA 01/2006
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2006
1	FluorineIBA 09/2004
1	Guanidine (Guanidine Nitrate)FDA Link 04/2004
1	somatostatin receptor 2IBA 05/2003
1	N- succinimidyl- 5- iodo- 3- pyridinecarboxylic acidIBA 01/2002

Therapy/Procedure

13	Therapeutics 05/2022 - 04/2004
4	Radiotherapy 01/2018 - 05/2003
3	Drug Therapy (Chemotherapy) 01/2011 - 04/2006
1	Castration 07/2018
1	Intravenous Administration 12/2017
1	Photothermal Therapy 01/2015
1	Precision Medicine 01/2015
1	Lasers (Laser) 01/2015
1	Radioimmunotherapy 02/2009
1	Intravenous Injections 03/2004